Akebia Therapeutics (AKBA) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Akebia Therapeutics (AKBA) has outperformed Jyong Biotech (MENS) over the past year, losing 75.1% versus a loss of 95.3%. Jyong Biotech is the larger company by market cap ($110.2 million vs $107.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | MENS |
|---|---|---|
| Share price | $0.3855 | $1.45 |
| Market cap | $107.04M | $110.24M |
| 1-day change | -8.71% | -17.14% |
| YTD return | -76.06% | -63.29% |
| 1-year return | -75.13% | -95.28% |
| 5-year return | -85.56% | — |
| EPS (TTM) | $-0.17 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $236.20M | — |
| Revenue growth (YoY) | +47.46% | — |
| Net income (latest FY) | $-5.34M | $-4.67M |
| Gross margin | 83.29% | — |
| Operating margin | 9.95% | — |
| Net margin | -2.26% | — |
| 52-week high | $1.73 | $38.88 |
| 52-week low | $0.361 | $1.43 |
| Distance from 52-week high | -77.72% | -96.27% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +678.21% | — |
| Average volume | 8.05M | 44.23K |
| Shares outstanding | 277.66M | 74.23M |
| Employees | 194 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AKBA has outperformed MENS by 20.2 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
AKBA vs MENS FAQ
Which is bigger, Akebia Therapeutics or Jyong Biotech?
Jyong Biotech (MENS) is larger, with a market capitalization of $110.24M compared with $107.04M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or MENS?
AKBA returned -75.13% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.